



## Clinical trial results:

### A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa with Continued Access to Emtricitabine

#### Summary

EudraCT number	2015-000304-26
Trial protocol	Outside EU/EEA
Global end of trial date	13 February 2017

#### Results information

Result version number	v1 (current)
This version publication date	27 August 2017
First version publication date	27 August 2017

#### Trial information

##### Trial identification

Sponsor protocol code	GS-US-162-0112
-----------------------	----------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00743340
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Clinical Trials Mailbox, Gilead Sciences International Ltd., ClinicalTrialDisclosures@gilead.com
Scientific contact	Clinical Trials Mailbox, Gilead Sciences International Ltd., ClinicalTrialDisclosures@gilead.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 February 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	13 February 2017
Global end of trial reached?	Yes
Global end of trial date	13 February 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The objectives of this trial were to provide FTC-203 study participants in South Africa with continued access to the study drug, emtricitabine, following completion of the FTC-203 study and to collect long-term safety information in participants receiving emtricitabine in combination with other antiretroviral agents.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.

This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	22 November 2005
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	South Africa: 50
Worldwide total number of subjects	50
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	43

Adolescents (12-17 years)	7
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled at 2 study sites in South Africa. The first participant was screened on 22 November 2005. The last study visit occurred on 13 February 2017.

### Pre-assignment

Screening details:

59 participants were screened.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Emtricitabine
------------------	---------------

Arm description:

Emtricitabine administered once daily

Arm type	Experimental
Investigational medicinal product name	Emtricitabine
Investigational medicinal product code	
Other name	FTC, Emtriva®
Pharmaceutical forms	Capsule, Oral solution
Routes of administration	Oral use

Dosage and administration details:

6 mg/kg capsule, up to a maximum of 200 mg once daily, or 10 mg/mL oral solution, up to a maximum of 240 mg once daily

Number of subjects in period 1	Emtricitabine
Started	50
Completed	9
Not completed	41
Subjects Rolled over to other Gilead Study	23
Withdrawal from the Study	5
Study medication non-compliance	1
Pregnancy	1
Virologic Failure	8
Protocol Violation	1
Subject Relocated	1
Lost to follow-up	1



## Baseline characteristics

### Reporting groups

Reporting group title	Emtricitabine
-----------------------	---------------

Reporting group description:

Emtricitabine administered once daily

Reporting group values	Emtricitabine	Total	
Number of subjects	50	50	
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	8		
standard deviation	± 2.5	-	
Gender categorical			
Units: Subjects			
Female	24	24	
Male	26	26	
Ethnicity			
Units: Subjects			
Black	49	49	
Other	1	1	

## End points

### End points reporting groups

Reporting group title	Emtricitabine
Reporting group description: Emtricitabine administered once daily	

### Primary: Number of Participants Who Had Access to, and Received the Intervention

End point title	Number of Participants Who Had Access to, and Received the Intervention <sup>[1]</sup>
-----------------	--

End point description:

This endpoint has been included to satisfy the requirements of EU-CTR. However, there were no prespecified endpoints in this study.

End point type	Primary
----------------	---------

End point timeframe:

Up to 586 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical comparison was planned or performed.

End point values	Emtricitabine			
Subject group type	Reporting group			
Number of subjects analysed	50			
Units: Participants				
number (not applicable)	50			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

Up to 586 weeks + 30 days

Adverse event reporting additional description:

- 1) Safety Analysis Set: all enrolled participants who have received at least 1 dose of study drug
- 2) One participant who resulted in incomplete abortion (System order class: Pregnancy, puerperium and perinatal conditions; Event term: Abortion incomplete) was not counted as part of SAE but was counted under pregnancies.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	20.0

### Reporting groups

Reporting group title	Emtricitabine
-----------------------	---------------

Reporting group description:

Emtricitabine 6 mg/kg capsule once daily, up to a maximum of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Nonserious/other adverse events were not collected for this study.

Serious adverse events	Emtricitabine		
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 50 (26.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Investigations			
Weight decreased			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hand fracture			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Lower limb fracture			
subjects affected / exposed	2 / 50 (4.00%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Overdose			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Essential hypertension			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Abortion incomplete			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Pyrexia			

subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Swelling			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Breast enlargement			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Epistaxis			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Attention deficit/hyperactivity disorder			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Conduct disorder			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reactive attachment disorder of infancy or early childhood			

subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Infections and infestations</b>			
Appendicitis			
subjects affected / exposed	2 / 50 (4.00%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Post procedural sepsis			
subjects affected / exposed	1 / 50 (2.00%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Emtricitabine		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 50 (0.00%)		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
24 July 2013	<ul style="list-style-type: none"><li>• Update of the Medical Monitor of the study</li><li>• Clarified the location of the sponsor</li><li>• Clarification that potential genotypic analysis samples needed will not be shipped to Gilead Sciences, Inc.</li><li>• Update to the Principle Investigator at the Infectious Disease Clinical Trial Unit study center</li><li>• Clarification to the clinic visits in which subject height and weight is to be taken.</li><li>• Update to Study Procedures Table, to clarify that HIV-1 Viral RNA levels are to be taken at every visit, and to clarify when subject height and weight should be measured</li><li>• Update to the acceptable methods of contraception requirements in the Inclusion Criteria</li><li>• Update to the date of the mentioned Investigator's Brochure for emtricitabine to the eleventh edition, dated 30 June 2010</li><li>• Update to the storage and handling requirements for emtricitabine oral solution</li><li>• Update of the safety reporting of Special Situations based on CT3 Guidance from the European Commission</li><li>• Update to the contraception requirements for the study based on current recommendations for use with emtricitabine</li><li>• Update to Emtricitabine (Emtriva®) Dose Tables to reflect the current dosing guidelines recommended for Emtricitabine capsules, 200mg.</li><li>• Updated current GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported